Current reports
6-K
Current report (foreign)
6 Mar 24
6-K
Calliditas Year-end report, January – December 2023
21 Feb 24
6-K
Calliditas Therapeutics appoints Maria Törnsén as President North America
8 Jan 24
6-K
Current report (foreign)
27 Dec 23
6-K
Current report (foreign)
20 Dec 23
6-K
Current report (foreign)
11 Dec 23
6-K
Current report (foreign)
30 Nov 23
6-K
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy
24 Nov 23
6-K
Interim Report January – September 2023 Q3
7 Nov 23
6-K
Calliditas Therapeutics’ nomination committee composition for the AGM 2024
23 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
12 Jun 23
F-3
Shelf registration (foreign)
28 Jun 22
424B5
Prospectus supplement for primary offering
12 Aug 21
F-3ASR
Automatic shelf registration (foreign)
12 Jul 21
RW
Registration withdrawal request
4 Feb 21
F-1
Registration statement (foreign)
26 Jan 21
DRS
Draft registration statement
29 Dec 20
S-8
Registration of securities for employees
27 Jul 20
424B4
Prospectus supplement with pricing info
8 Jun 20
F-1MEF
Registration statement to add securities to prior F-1 registration
4 Jun 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
11 Jul 22
CORRESP
Correspondence with SEC
7 Jul 22
UPLOAD
Letter from SEC
6 Jul 22
EFFECT
Notice of effectiveness
5 Jun 20
EFFECT
Notice of effectiveness
5 Jun 20
CORRESP
Correspondence with SEC
4 Jun 20
SEC STAFF LETTER
SEC staff letter
4 Jun 20
CERT
Certification of approval for exchange listing
3 Jun 20
UPLOAD
Letter from SEC
3 Jun 20
CORRESP
Correspondence with SEC
2 Jun 20
Ownership
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND
1 Feb 23
SC 13G
Swedbank Robur Fonder AB
26 Jan 23
SC 13G
Linc AB
2 Mar 22
SC 13G
Swedbank Robur Fonder AB
14 Feb 22
SC 13G
FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND
14 Feb 22
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
12 Nov 20
SC 13G
BIOTECHNOLOGY VALUE FUND L P
8 Jun 20